Gsk Plc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Gsk Plc (GSK) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Gsk Plc vs Its Competitors
- TTM: Trailing 12-month revenue of 43,094M vs 442,018M combined for its competitors (8.9% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months), vs accelerating (+35.1%) for its tracked peer group.
- Growth: Gsk Plc generated 37.4% revenue growth year over year in Q4 2025, vs 8.1% for its competitors combined.
- Profitability: Its 19.3% net margin compares with 14.0% for the peer group.
- Scale: Gsk Plc ranks #14 of 545 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 1.8% of industry market cap.
- Peer revenue share: Gsk Plc accounted for 22.4% of combined revenue among its tracked peer group, up from 18.5% a year earlier.
- Peer differentiation: Revenue per employee of $169.66M compares with $1.07M for the peer group (157.9x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
GSK Sales vs. its Competitors, Q4 2025
Gsk Plc reported revenue growth of 37.35 % year on year in Q4 2025, above its competitors' combined revenue growth of 8.13 %.
With a net margin of 19.25 %, Gsk Plc achieved higher profitability than its competitors (13.98 %).
Gsk Plc generated 22.40 % of the combined sales of its peer group, up from 18.52 % a year earlier.
API endpoints for this dataset
Gsk Plc vs. its Competitors, Q4 2025
Revenue growth, year on year
Net income growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Gsk Plc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Gsk Plc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Gsk Plc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (44) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (10) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (6) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Gsk Plc's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 8.9% year over year, combined, vs 37.4% for Gsk Plc. Gsk Plc's share of combined industry revenue moved from 6.53% to 8.24%, a gain of 1.70 percentage points.
Gsk Plc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Gsk Plc | Yes | Yes | No | No |
| Competitors combined (68) | ||||
| High-Confidence Competitors (60) | ||||
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 100.00 % (8 of 8) | 100.00 % (8 of 8) | 50.00 % (4 of 8) | 0.00 % (0 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
GSK Stock Performance relative to its Competitors
GSK Stock Performance relative to High-Confidence Competitors
GSK Stock Performance relative to Similar-Size Competitors
GSK Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Moderna Inc | 282.9% | Outperformed |
| 2 | Cypherpunk Technologies Inc | 282.9% | Outperformed |
| 3 | Verona Pharma Plc | 282.9% | Outperformed |
| 4 | An2 Therapeutics Inc | 282.9% | Outperformed |
| 5 | 180 Life Sciences Corp | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Gsk Plc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Gsk Plc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Gsk Plc |
212,190.18 | 43,093.89 |
 Eli Lilly And Company |
1,261,319.90 | 86,462.00 |
 Johnson and Johnson |
690,774.55 | 99,335.00 |
 Merck and Co Inc |
367,313.70 | 66,569.00 |
 Pfizer Inc |
168,101.73 | 63,625.00 |
 Bristol myers Squibb Company |
127,573.42 | 50,033.00 |
| SUBTOTAL | 3,213,054.90 | 486,395.23 |
Sign in to see all competitors of Gsk Plc.
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Gsk Plc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Gsk Plc's Competitors Named by the Company
Competitive relationships identified from Gsk Plc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Compass Therapeutics Inc | Company report | 85% |
| Neximmune Inc | Company report | 85% |
| Ngm Biopharmaceuticals Inc | Company report | 85% |
| Propanc Biopharma Inc | Company report | 85% |
| Janux Therapeutics Inc | Company report | 85% |
| Mirum Pharmaceuticals Inc | Company report | 85% |
| Assembly Biosciences Inc | Company report | 85% |
| Innoviva Inc | Company report | 85% |
| Arcellx Inc | Company report | 85% |
| Sagimet Biosciences inc | Company report | 85% |
| Arbutus Biopharma Corp | Company report | 85% |
| Coherus Oncology inc | Company report | 85% |
| Vaxcyte Inc | Company report | 85% |
| Enanta Pharmaceuticals Inc | Company report | 85% |
| Inventiva S a | Company report | 85% |
| Contineum Therapeutics Inc | Company report | 85% |
| Trevi Therapeutics Inc | Company report | 85% |
| Achieve Life Sciences Inc | Company report | 85% |
| Chemomab Therapeutics Ltd | Company report | 85% |
| Koninklijke Philips Nv | Company report | 85% |
| Cannaisseur Group Inc. | Company report | 85% |
| Barinthus Biotherapeutics Plc | Company report | 85% |
| Electrocore Inc | Company report | 85% |
| Akero Therapeutics Inc | Company report | 85% |
| Bright Minds Biosciences Inc | Company report | 85% |
| 22nd Century Group inc | Company report | 85% |
| Scinai Immunotherapeutics Ltd | Company report | 85% |
| Nextcure Inc | Company report | 85% |
| Dynavax Technologies Corporation | Company report | 85% |
| Kiromic Biopharma Inc | Company report | 85% |
| Nuvation Bio Inc | Company report | 85% |
| Scynexis Inc | Company report | 85% |
| Acorda Therapeutics Inc | Company report | 85% |
| Vaxxinity Inc | Company report | 85% |
| Notable Labs Ltd | Company report | 85% |
| Vincerx Pharma Inc | Company report | 85% |
| ACOR | Company report | 85% |
| Samsara Luggage Inc | Company report | 85% |
| Prestige Consumer Healthcare Inc | Company report | 85% |
| Novavax inc | Company report | 85% |
| Immutep Limited | Company report | 85% |
| Mirati Therapeutics Inc | Company report | 85% |
| Sutro Biopharma Inc | Company report | 85% |
| Immunome Inc | Company report | 85% |
| Cytodyn inc | Company report | 85% |
| Sab Biotherapeutics Inc | Company report | 85% |
| Tscan Therapeutics Inc | Company report | 85% |
| Altamira Therapeutics Ltd | Company report | 85% |
| Bonk Inc | Company report | 85% |
| SHOT | Company report | 85% |
| Grace Therapeutics Inc | Company report | 85% |
| Vir Biotechnology Inc | Company report | 85% |
| Nurix Therapeutics Inc | Company report | 85% |
| Scholar Rock Holding Corp | Company report | 85% |
| Lunai Bioworks Inc | Company report | 85% |
| Big Digital Energy Inc | Company report | 85% |
| Kalvista Pharmaceuticals Inc | Company report | 85% |
| ACST | Company report | 85% |
| Anavex Life Sciences Corp | Company report | 85% |
| MIGI | Company report | 85% |
| Alector Inc | Company report | 85% |
| RENB | Company report | 85% |
| Nascent Biotech Inc | Company report | 85% |
| Agios Pharmaceuticals Inc | Company report | 85% |
| Bicycle Therapeutics Plc | Company report | 85% |
| C4 Therapeutics Inc | Company report | 85% |
| Ladrx Corporation | Company report | 85% |
| Xencor Inc | Company report | 85% |
| Akebia Therapeutics Inc | Company report | 85% |
| Indaptus Therapeutics Inc | Company report | 85% |
| Canton Strategic Holdings Inc | Company report | 85% |
| Edesa Biotech Inc | Company report | 85% |
| Moderna Inc | Company report | 85% |
| Allarity Therapeutics Inc | Company report | 85% |
| Inovio Pharmaceuticals Inc | Company report | 85% |
| Vistagen Therapeutics Inc | Company report | 85% |
| Adc Therapeutics Sa | Company report | 85% |
| Imunon Inc | Company report | 85% |
| Optinose Inc | Company report | 85% |
| Eli Lilly And Company | Company report | 85% |
| Sanofi | Company report | 85% |
| Merck and Co Inc | Company report | 85% |
| Pfizer Inc | Company report | 85% |
| Emergent Biosolutions Inc | Company report | 85% |
| Johnson and Johnson | Company report | 85% |
| Taro Pharmaceutical Industries Ltd | Company report | 85% |
| Bristol myers Squibb Company | Company report | 85% |
| Curevac N v | Company report | 85% |
| Regeneron Pharmaceuticals Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Gsk Plc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Gsk Plc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Eli Lilly And Company | Reportable 100.00 % |
| Johnson and Johnson | Oncology 29.93 % |
| Merck and Co Inc | Pharmaceutical segment 89.95 % |
| Pfizer Inc | U.S. Commercial Division 58.35 % |
| Xencor Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Gsk Plc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Gsk Plc | 212,190 | 169,660,977 | 32,662,867 |
| Eli Lilly And Company | 1,261,320 | 1,729,240 | 551,594 |
| Johnson and Johnson | 690,775 | 705,504 | 114,311 |
| Merck and Co Inc | 367,314 | 887,587 | 42,267 |
| Pfizer Inc | 168,102 | 848,333 | 54,160 |
| Bristol myers Squibb Company | 127,573 | 1,539,477 | 284,338 |
| PEERS TOTAL | 3,000,865 | 1,074,719 | 156,884 |
Gsk Plc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Eli Lilly And Company | United States 62.04 % |
| Johnson and Johnson | United States 58.90 % |
| Merck and Co Inc | EMEA 21.50 % |
| Pfizer Inc | United States 63.93 % |
| Bristol myers Squibb Company | United States 69.43 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Gsk Plc's Position in Industry Market Structure
Market-capitalization share and concentration across all 495 companies in Gsk Plc's industry classification, broader than the peer set above. Market cap in millions of $.Gsk Plc ranks #14 of 495 companies by market capitalization in its industry, holding 1.76 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 888, indicating a unconcentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,261,743 | 21.10 % |
| 2 | Johnson and Johnson | 688,377 | 11.51 % |
| 3 | Beone Medicines Ltd | 628,233 | 10.51 % |
| 4 | Abbvie Inc | 519,434 | 8.69 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Astrazeneca Plc | 1,234 | 5.2% |
| 14 | Gsk Plc | 105,247 | 1.76 % |
Market cap and industry share for the rest of Gsk Plc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-11-09.
Gsk Plc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 9 | Pfizer Inc | 166,582 | 17.53 % |
| 10 | Astrazeneca Plc | 147,914 | 12.95 % |
| 11 | Vertex Pharmaceuticals Inc | 140,582 | 29.99 % |
| 12 | Bristol myers Squibb Company | 127,263 | 33.68 % |
| 13 | Sanofi | 1,234 | 12.3% |
| 14 | Gsk Plc | 105,247 | 7.56 % |
| 15 | Regeneron Pharmaceuticals Inc | 1,234 | 12.3% |
| 16 | Teva Pharmaceutical Industries Limited | 1,234 | 12.3% |
| 17 | Royalty Pharma Plc | 1,234 | 12.3% |
| 18 | Spyre Therapeutics Inc | 1,234 | 12.3% |
| 19 | Zoetis Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Gsk Plc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-11-09. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Gsk Plc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (445 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 54.88 % | 37.84 % (avg) | +17.0 pp |
| Operating Margin | 24.28 % | industry median | +19.1 pp |
| EBITDA Margin | 29.74 % | -6.50 % (avg) | +36.2 pp |
| Capital Intensity (Capex / Revenue) | 4.13 % | 7.56 % (avg) | -3.4 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Gsk Plc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (445 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 33.6x | 26.6x | +7.0x |
| EV / EBITDA | - | 15.5x | - |
| P/B | - | 4.3x | - |
| Return on Equity | 38.67 % | industry aggregate | 18.55 % |
| Return on Invested Capital | 26.21 % | -9.84 % (avg) | 36.05 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Gsk Plc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue Growth | 4.00 % | 6.29 % | 7.46 % |
| Operating Margin | 22.24 % | 12.82 % | 24.28 % |
| Return on Invested Capital | 13.64 % | 17.31 % | 26.21 % |
| P/E | 29.9x | 57.9x | 33.6x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Gsk Plc's Strategic Group Map
Gsk Plc is shown in red; its closest peers by combined growth, margin and ROIC are labeled. See Methodology: Strategic Group Map for how this chart is built.
Gsk Plc's trailing-12-month revenue growth of 7.5% and operating margin of 24.3% compares with an average of 7.8% growth and 24.1% margin across its 8 closest peers by combined growth, margin and ROIC -- Gsk Plc sits below that peer average on growth and above it on margin.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Gsk Plc's BCG Growth-Share Matrix
See Methodology: BCG Growth-Share Matrix for how relative share and growth are calculated and thresholded.
Gsk Plc falls in the Dog quadrant: relative market share of 0.08x vs its largest competitor, in an industry growing revenue 8.1% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Gsk Plc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 888 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 4.13 % vs industry average 7.56 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Gsk Plc's dedicated Suppliers and Customers pages, not here.
Gsk Plc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Gsk Plc falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Gsk Plc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 19.1 points above the industry median.
- Return on equity 18.6 points above the industry aggregate.
- Latest-quarter revenue run-rate is accelerating (+300.0% annualized vs trailing 12 months).
Weaknesses
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.08x).
Opportunities
- A meaningful share of competitors (53.80 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: see Methodology: SWOT Analysis.
Gsk Plc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Gsk Plc | 0.16 | 0.82 | 0.87 |
| Eli Lilly And Company | 0.16 | 1.44 | 1.44 |
| Johnson and Johnson | 0.36 | 1.04 | 0.60 |
| Merck and Co Inc | 0.40 | 1.46 | 1.01 |
| Pfizer Inc | 0.04 | 1.27 | 0.72 |
| Bristol myers Squibb Company | 0.48 | 1.44 | 2.12 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Gsk Plc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Gsk Plc | Q4 2025 | +7.5 % | +120.0 % |
| Eli Lilly And Company | Q3 2026 | +38.6 % | +15.6 % |
| Johnson and Johnson | Q3 2026 | +5.9 % | -95.9 % |
| Merck and Co Inc | Q2 2026 | +5.1 % | - |
| Pfizer Inc | Q3 2026 | -0.4 % | -8.7 % |
| Bristol myers Squibb Company | Q3 2026 | +6.9 % | -1.5 % |
| PEERS TOTAL | +11.0 % | -6.2 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Gsk Plc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Gsk Plc | Q4 2025 | +7.2 % | -0.6 % |
| Eli Lilly And Company | Q3 2026 | +30.7 % | +52.2 % |
| Johnson and Johnson | Q3 2026 | +10.9 % | +17.7 % |
| Merck and Co Inc | Q2 2026 | +23.6 % | +16.9 % |
| Pfizer Inc | Q3 2026 | -3.5 % | -4.8 % |
| Bristol myers Squibb Company | Q3 2026 | +20.7 % | +7.5 % |
Gsk Plc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Gsk Plc | 10.09% | 44.94% | 38.67% |
| Eli Lilly And Company | 21.24% | 32.00% | 83.65% |
| Johnson and Johnson | 8.06% | 10.53% | 19.55% |
| Merck and Co Inc | 2.42% | 3.24% | 6.59% |
| Pfizer Inc | 1.98% | 2.34% | 4.62% |
| Bristol myers Squibb Company | 10.47% | 13.59% | 43.83% |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Gsk Plc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Gsk Plc | 37.13 | 4.92 |
| Eli Lilly And Company | 45.84 | 14.59 |
| Johnson and Johnson | 42.68 | 6.95 |
| Merck and Co Inc | 119.93 | 5.52 |
| Pfizer Inc | 41.60 | 2.64 |
| Bristol myers Squibb Company | 13.77 | 2.55 |
| PEERS AVERAGE | 44.01 | 6.61 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.